3.7 Screening Testing (including Newborn Screening)
Key Takeaways
- Screening tests risk-stratify asymptomatic populations; they are not definitive diagnoses and require confirmatory testing after positive screens.
- Wilson–Jungner principles (condition importance, acceptable test, treatment availability, program infrastructure) conceptually justify public screening programs such as newborn screening (NBS).
- NBS prioritizes treatable conditions of early onset; positive screens generate urgency for confirmatory labs and specialty referral, not immediate lifelong labeling from the screen alone.
- False positives, incidental findings (for example, carrier status or maternal disease on some platforms), and residual risk after negative screens are core counseling themes.
- Population screening differs from diagnostic testing in pretest probability, consent model, and how results change next steps.
Screening vs diagnostic testing
| Feature | Screening | Diagnostic testing |
|---|---|---|
| Population | Asymptomatic or average-risk groups (or defined high-risk screen cohorts) | Individuals with phenotype or high clinical suspicion |
| Pretest probability | Usually low | Higher |
| Goal | Risk stratification; identify who needs more testing | Establish or refute a specific diagnosis |
| Positive result meaning | Increased risk / needs confirmation | Supports a clinical-molecular diagnosis (with correlation) |
| Negative result meaning | Lowered but not always zero residual risk | Does not always exclude disease (assay limits) |
| Program design | Sensitivity prioritized; some false positives accepted | Specificity and interpretive accuracy emphasized |
One-line board definition: Screening sorts; diagnosis decides. A newborn screen “positive for possible PKU” is not the same as a biochemical + molecular confirmation of phenylketonuria.
Wilson–Jungner principles (conceptual, high-yield)
The classic Wilson–Jungner criteria (WHO, 1968) were written for public health screening generally. Genetic counselors are not expected to recite every historical bullet verbatim, but you must recognize the spirit of justified screening:
| Principle (conceptual) | Application to genetic NBS |
|---|---|
| Important health problem | Early-onset conditions with serious morbidity/mortality |
| Accepted treatment / management | Dietary therapy, enzyme replacement, antibiotics, transplant pathways, etc. |
| Facilities for diagnosis and treatment | Confirmatory labs, metabolic/genetics clinics, care networks |
| Recognizable latent or early stage | Presymptomatic newborns |
| Suitable test | Acceptable dried-blood-spot assays with defined cutoffs |
| Test acceptable to population | Heel-stick programs embedded in perinatal care |
| Natural history understood | Enough to know early treatment helps |
| Agreed policy on whom to treat | Protocols for screen-positive infants |
| Cost balanced vs case-finding | Public health program economics |
| Continuous process, not one-off | Quality assurance, follow-up, panel review |
Modern genomic NBS debates ask whether actionability, parental interest, and equity should expand panels beyond classic Wilson–Jungner thresholds. For the exam, flag when a stem proposes screening for an untreatable adult-onset condition in newborns without program infrastructure—that usually fails screening logic.
Newborn screening (NBS): what counselors must know
Core features
- Timing: Dried blood spot typically collected ~24–48 hours after birth (state protocols vary).
- Mandate model: Most U.S. NBS is public health–mandated with limited parental opt-out (varies by jurisdiction)—distinct from clinical diagnostic consent.
- Recommended Uniform Screening Panel (RUSP): Federal advisory list that states largely follow but may expand; exact conditions remain state-specific.
- Condition classes: Inborn errors of metabolism, endocrinopathies, hemoglobinopathies, cystic fibrosis, hearing loss screening (physiologic), critical congenital heart disease (pulse oximetry), spinal muscular atrophy and SCID in many programs, and others as panels evolve.
From screen to diagnosis — the pathway
- Primary screen (often tandem mass spectrometry for metabolites; DNA assays for some conditions; enzyme/immunoreactive trypsinogen algorithms for CF).
- Out-of-range / positive / borderline result triggers urgent contact.
- Confirmatory testing (plasma amino acids, urine organic acids, enzyme assay, diagnostic gene testing, sweat chloride, immunology studies, etc.).
- Specialty management begins based on confirmatory results—not on the screen alone.
| Screen result language | Counselor translation |
|---|---|
| Negative / in-range | Condition much less likely; residual risk remains (timing, transfusion, mild variants, lab error) |
| Borderline / inconclusive | Repeat screen or additional labs; avoid premature reassurance or alarm |
| Positive / out-of-range | Needs prompt confirmatory evaluation; not a final diagnosis |
| Carrier detection (some DNA-based screens) | May identify infant carriers or parental implications without disease |
False positives and why they happen
NBS cutoffs favor sensitivity (miss fewer true cases), so false positives are expected. Contributors include:
- Prematurity, total parenteral nutrition, illness, or timing of collection
- Carrier status or mild biochemical variants that cross cutoffs
- Maternal conditions affecting the neonate’s metabolites (for example, maternal vitamin B12 deficiency patterns)
- Laboratory or sample quality issues
Counseling stance after a positive screen: Acknowledge parental anxiety, explain that most screen-positives are not confirmed disease for many conditions, but emphasize why rapid follow-up still matters—true positives need early treatment.
False negatives and residual risk
A negative NBS does not eliminate clinical vigilance. Late-onset variants, conditions not on the state panel, sample collected too early, transfusion effects, and rare assay failures can produce missed cases. If the phenotype later suggests a screenable disease, pursue diagnostic testing regardless of NBS history.
Other genetic screening contexts (beyond NBS)
Domain 3B “screening” also includes:
| Context | Example | Key counseling point |
|---|---|---|
| Prenatal aneuploidy screening | NIPT, serum analytes | Screen ≠ diagnostic CVS/amnio |
| Carrier screening | Expanded panels (see next section) | Reproductive risk, not personal disease diagnosis for AR carriers |
| Population cancer screening genes (emerging/ limited) | Not equivalent to indication-based hereditary cancer testing | Criteria and utility differ from diagnostic oncology genetics |
| Cascade “screening” language misuse | Relatives tested for known variant | That is cascade/predictive testing, not population screening |
Trap: Calling NIPT a “diagnostic test for Down syndrome” is wrong; diagnostic confirmation requires diagnostic prenatal procedures/cytogenomic testing.
Consent, equity, and psychosocial issues in screening programs
- Mandated NBS still deserves understandable education; parents may not recall what was screened.
- Incidental findings on DNA-based NBS (carrier status, variants related to adult disease, maternal disease signals) create counseling complexity.
- Equity: Program quality depends on follow-up access; a “free screen” without reachable confirmatory care fails Wilson–Jungner infrastructure expectations.
- Stigma and labeling: Avoid treating screen-positive infants as diagnosed until confirmatory testing completes.
Worked scenario A
Parents call frantically: “The state says our baby is positive for maple syrup urine disease.” Best response elements: validate fear; explain screening vs diagnosis; arrange same-day/urgent metabolic confirmatory labs and clinical evaluation; advise holding dietary changes only as directed by the metabolic team; do not wait weeks for a routine pediatric visit.
Worked scenario B
A toddler presents with developmental regression; NBS was normal. Can the child still have a metabolic disorder? Yes—residual risk and non-panel conditions remain. Proceed with phenotype-driven diagnostic evaluation.
Worked scenario C
A health system proposes screening all newborns with genome sequencing for adult-onset Alzheimer risk alleles. Critique using screening principles: limited early treatment benefit, psychosocial harm, right-not-to-know for the child, and weak fit with classic public-health screening justification.
Exam scenarios and traps
- Trap — treating a positive screen as a diagnosis. Confirmation is mandatory.
- Trap — absolute reassurance after negative NBS when clinical suspicion is high.
- Trap — applying diagnostic pretest counseling scripts unchanged to mandated NBS. Consent models differ, but education and follow-up counseling still matter.
- Trap — confusing carrier screening with NBS. Different goals, timing, and result meanings.
- Scenario: CF NBS algorithms may use IRT ± DNA; an identified infant carrier needs parental counseling and possibly parental testing, not a CF diagnosis for the infant.
Practice checkpoints
- Contrast screening vs diagnostic goals in one table in your mind.
- Name why false positives are tolerated in NBS.
- List what happens after an out-of-range newborn screen.
- Apply Wilson–Jungner thinking to reject poorly justified genomic screens.
A newborn’s state screen is out-of-range for a metabolic condition. What is the most accurate counseling statement?
Which statement best reflects the conceptual role of Wilson–Jungner principles in newborn screening?
A child later develops clinical signs of a condition that was on the state’s newborn screening panel, but the newborn screen was reported normal. What is the best next concept to apply?
How does population newborn screening most clearly differ from diagnostic genetic testing in a symptomatic child?